

Indication	Target	Candidate	Research	Hit	Lead	Pre-clinic	Phase I	Phase II	Sponsor / Licensee	
PDAC CRC, GBM, Ewing Sarcoma, Melanoma	Neurotensin Receptor (NTR)	IPN-01087 3BP-227								
		NN								
Solid Tumors	Fibroblast Activation Protein α (FAP)	FAP-2286							 Europe	 US, RoW (ex Europe)
Neuroendocrine Tumors	Gastric Inhibitory Polypeptide Receptor (GIP-R)	3B-401								
		3B-402								
CAIX Expressing Tumors	Carbonic Anhydrase IX (CAIX)	Debio 0228								
Solid Tumors	Undisclosed	NTA								
Solid Tumors	Undisclosed	NTB								
Solid Tumors	Undisclosed	NTC								
Solid Tumors	Undisclosed	3BP								
Solid Tumors	Undisclosed	3BP								
Solid Tumors	Undisclosed	3BP								

THERAPEUTIC RADIOPHARMACEUTICAL
 DISTINCT SPECT OR PET IMAGING AGENT

Indication	Target	Candidate	Research	Hit	Lead	Pre-clinic	Phase I	Phase II	Sponsor / Licensee
PDAC CRC, GBM, Ewing Sarcoma, Melanoma	Neurotensin Receptor (NTR)	IPN-01087 3BP-227 NN							
Solid Tumors	Fibroblast Activation Protein α (FAP)	FAP-2286							3B Pharmaceuticals Europe CLOVIS ONCOLOGY US, RoW (ex Europe)
Neuroendocrine Tumors	Gastric Inhibitory Polypeptide Receptor (GIP-R)	3B-401 3B-402							3B Pharmaceuticals
CAIX Expressing Tumors	Carbonic Anhydrase IX (CAIX)	Debio 0228							Debiopharm
Solid Tumors	Undisclosed	NTA							CLOVIS ONCOLOGY
Solid Tumors	Undisclosed	NTB							CLOVIS ONCOLOGY
Solid Tumors	Undisclosed	NTC							CLOVIS ONCOLOGY
Solid Tumors	Undisclosed	3BP							3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP							3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP							3B Pharmaceuticals

THERAPEUTIC RADIOPHARMACEUTICAL
 DISTINCT SPECT OR PET IMAGING AGENT